Prenoxdiazine
Trade name: Libexin
Small moleculeexperimental
Prenoxdiazine is a cough suppressant. It acts peripherally by desensitizing the pulmonary stretch receptors. Therefore, there's a reduction of cough impulses originating in the lungs. Prenoxdiazine is indicated in cough of bronchial origin. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 9, 2016 (NCT03837938)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPrenoxdiazine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03837938 | Phase 3 | Nov 9, 2016 | Dompe Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dompe Pharmaceuticals | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1